Dr. Reddy's appoints Sunil Gavaskar as the brand ambassador for its #TensionMatLo campaign

The campaign seeks to raise awareness about hypertension while emphasising the significance of managing blood pressure for a healthier lifestyle

Enhertu to demonstrate a significant survival benefit vs. chemotherapy

ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer

Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy

OS-SiA digital pathology scanner developed by OptraSCAN granted US patent

OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights

Agilent companion diagnostic expands CE-IVD Mark in Europe to include cervical cancer

Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020

Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer

Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers

Experts say extended day prescription refills for hypertension can be a game-changer

The recently released WHO guideline on hypertension treatment (2021), recommends that patients with stable blood pressure can be asked to visit clinics at 3-6 month intervals as an important strategy to improve hypertension control

Enhertu Phase III results to redefine how metastatic breast cancer is classifed

Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.

ISA celebrates October as stroke awareness month

India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50